Sommerhalder, David

A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial

Ma, Y., Yang, Y., Huang, Y., Fang, W., Xue, J., Meng, X., Fan, Y., Fu, S., Wu, L., Zheng, Y., et al. (2025) · Nature Medicine

Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and Biomarkers

Cited by 122

Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer

Wolpin, B. M., Park, W., Garrido-Laguna, I., Spira, A., Starodub, A., Sommerhalder, D., Punekar, S. R., Barve, M., Pelster, M., Herzberg, B., et al. (2026) · New England Journal of Medicine

Pancreatic and Hepatic Oncology ResearchProtein Kinase Regulation and GTPase Signaling

Cited by 90

Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C (ON) inhibitor, in patients with or without prior KRASG12C (OFF) inhibitor treatment

Jänne, P. A., Bigot, F., Papadopoulos, K., Eberst, L., Sommerhalder, D., Lebellec, L., Voon, P. J., Pellini, B., Kalinka, E., Arbour, K., et al. (2023) · Molecular Cancer Therapeutics

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 63

First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors.

Meric-Bernstam, F., Sharma, M., Sommerhalder, D., Skeel, R. T., El-Khoueiry, A. B., Caswell-Jin, J. L., Patel, P. H., & Rosen, E. (2022) · Journal of Clinical Oncology

RNA and protein synthesis mechanismsPI3K/AKT/mTOR signaling in cancer

Cited by 17

First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT-901 as monotherapy in patients with select advanced solid tumors.

Harvey, R. D., Falchook, G. S., Naqash, A. R., Kim, J. W., Dowlati, A., Le Bruchec, Y., Coudert, I., Ervin-Haynes, A. L., & Sommerhalder, D. (2022) · Journal of Clinical Oncology

Monoclonal and Polyclonal Antibodies ResearchSynthesis and pharmacology of benzodiazepine derivatives

Cited by 1